Experts addressed minimizing cardiovascular risk, managing diabetes in the ICU, altering protocols, and monitoring glucose levels, while studies looked at insulin infusion and other interventions for patients with COVID-19.
Experts gave advice on which diabetes drugs should be stopped in patients with COVID-19, and studies highlighted associations between the two diseases.
Recent studies analyzed data on lower-extremity amputations among patients with diabetes, including recent trends in this complication and its associated mortality, effects of the pandemic, and relationships with diabetes drugs.
Two recent studies analyzed the renal effects of medications for type 2 diabetes, one finding lower rates of acute kidney injury with sodium-glucose co-transporter-2 inhibitors and the other finding reduced onset of macroalbuminuria with liraglutide.
Recent studies looked at light therapy for depression and diabetes, seasonal variation in glycemic control, and associations between outdoor sunlight and temperature and metabolism.
Recent analyses of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial looked at the effects of fenofibrate on gout and cardiovascular events in patients with type 2 diabetes.
Two recent studies considered whether initiation of second-line therapies in patients already taking metformin for type 2 diabetes occurs too soon or too late.
Two recent studies looked at the effects of diabetes on the brain, one focusing on mild cognitive impairment and the other on brain imaging findings.
Older patients with diabetes were the focus of several recent studies, including one that looked at associations between glycemic control and mortality and two that compared second-line medication options.
One recent study reported on the development and validation of an artificial intelligence algorithm for detecting diabetic retinopathy, while another tested such technology in primary care.